Akari Other Current Liab from 2010 to 2024

AKTX Stock  USD 1.21  0.09  8.04%   
Akari Therapeutics Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2024. During the period from 2010 to 2024, Akari Therapeutics Other Current Liabilities regression line of annual values had r-squared of  0.09 and arithmetic mean of  4,961,841. View All Fundamentals
 
Other Current Liabilities  
First Reported
2014-12-31
Previous Quarter
3.1 M
Current Value
3.6 M
Quarterly Volatility
5.6 M
 
Yuan Drop
 
Covid
Check Akari Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akari Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 6.4 M, Selling General Administrative of 7.6 M or Other Operating Expenses of 18 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Akari financial statements analysis is a perfect complement when working with Akari Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Akari Therapeutics Correlation against competitors.

Latest Akari Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Akari Therapeutics PLC over the last few years. It is Akari Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Akari Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Akari Other Current Liab Regression Statistics

Arithmetic Mean4,961,841
Geometric Mean2,913,420
Coefficient Of Variation94.93
Mean Deviation3,662,883
Median4,228,000
Standard Deviation4,710,263
Sample Variance22.2T
Range16.5M
R-Value0.30
Mean Square Error21.8T
R-Squared0.09
Significance0.28
Slope312,414
Total Sum of Squares310.6T

Akari Other Current Liab History

20245.7 M
20232.9 M
202211.1 M
20214.3 M
20201.8 M
20194.2 M

About Akari Therapeutics Financial Statements

Akari Therapeutics investors use historical fundamental indicators, such as Akari Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Akari Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities2.9 M5.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.